The complaint alleges that Medicaid price controls implemented in the Inflation Reduction Act will negatively impact biopharmaceutical innovation.
Merck, known as MSD outside of the United States and Canada, announced that it had officially filed a complaint against the US government on June 6, 2023. According to a company statement, the complaint alleges that the price controls introduced by the Inflation Reduction Act (IRA), which require the Centers for Medicare and Medicaid Services to begin setting prices on small molecule medicines at nine years and large molecule medicines at 13 years, are unconstitutional and will stifle biopharmaceutical innovation.
The complaint cites the Fifth Amendment, which states that the US government must pay “just compensation” if it takes property for public use. In the statement, Merck argues that the IRA allows the government to coerce Merck to provide biopharmaceutical innovations without providing equitable value for them.
“Patients and the public need biopharmaceutical innovation to address global health challenges like cancer and Alzheimer’s disease, and the IRA is negatively affecting critical research and development,” reads the statement. “By changing the incentives and returns for some therapies and technologies over others, the IRA is changing the course of R&D, which in time will leave many patients without treatment options.”
“The Biden-Harris administration is going to fight attempts to go back to the way things were before,” said Karine Jean-Pierre, White House press secretary, in a statement to the press regarding the suit. “And so, we are confident we will succeed. There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices. Anytime profits of the pharmaceutical industry are challenged, they make claims about it hindering their ability to innovate.Not only are these arguments untrue, but the American people do not buy them.”
Source: Merck, White House
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.